The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 14 April 2026•Updated 16 April 2026•

1 min read

Cardiff Oncology, BayCom Corp, and Tango Therapeutics Announce Major Executive Leadership Changes

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1Cardiff Oncology appointed Mani Mohindru as permanent CEO, along with a new CFO and COO.

2BayCom Corp announced an executive leadership transition and the appointment of three new executives to drive growth strategy.

Nasdaq-listed firms Cardiff Oncology, BayCom Corp, and Tango Therapeutics have announced significant C-suite leadership transitions aimed at driving their next phases of corporate growth. Cardiff Oncology has officially appointed Mani Mohindru as permanent CEO, while BayCom Corp announced a leadership transition involving three new executives. Joining the trend, Tango Therapeutics appointed Matthew Gall as its new Chief Financial Officer (CFO), alongside additional leadership hires in clinical operations and corporate strategy. These strategic appointments at Tango are specifically designed to accelerate the late-stage development of its drug candidate, Vopimetostat. Analysts view these collective moves as a strategic effort to scale operations and enhance corporate governance across the biotech and financial sectors. While the leadership overhaul is a positive long-term signal, market impact is expected to remain neutral in the short term as investors await tangible clinical and financial results.

about 2 months ago

Version History

Version 1about 2 months ago

What changed: The story was updated to include new leadership appointments at Tango Therapeutics, including a new CFO to drive the clinical development of Vopimetostat.